Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This action is responsive to the claim set dated Dec. 3, 2024, in which claim 1 was newly amended and claims 16-27 were newly added. Claims 1-4 and 16-27 are pending and examined below.
Priority
The present application is a 35 U.S.C. 371 national stage filing of the International Application No. PCT/JP2023/007107, filed Feb. 27, 2023 and claims foreign priority 35 U.S.C. 119(a)-(d) to JP2022-119270 filed on July 27, 2022.
Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e).
Failure to provide a certified translation may result in no benefit being accorded for the non-English application.
Thus, the earliest possible priority for this application is July 27, 2022.
Information Disclosure Statement
The information disclosure statements filed Feb. 21,2025 and June 2, 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS has been considered by the examiner.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1-4 and 16-21 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. The claim(s) recite(s) a method of evaluating an observation object containing a hepatocyte, including an identification step (identifying the bile canaliculus region included in an observation object by using refractive index distribution) and an evaluation step (evaluating a bile canaliculus region on the basis of a parameter obtained from refractive index distribution data) or only an identification or evaluation step. The claims further recite a wherein step, which specifies that the bile canaliculus includes one parameter of an area of a cross section perpendicular to an axis of a tubular flow or cross section seen from a tomographic plane, a refractive index, the number of microvilli, or an average length of microvilli. This judicial exception is not integrated into a practical application because each of these steps appears to be mental. Even if the steps cannot be undertaken mentally, there is no recitation of any physical step; rather the outcome of something that might require a physical step is claimed. Neither the identification step nor the evaluation step results in any tangible, physical steps. A practitioner looking at a piece of paper or a computer screen could (or could not) be practicing the steps recited in this claim
With respect to dependent claims 2 and 3, the additional limitation is directed to how the bile canaliuculus is identified, and thus these are still abstract steps.
With respect to dependent claims 4, 16 and 17, these claims add limitations that refine the refractive index distribution data, which refines the identification step, but the claims still lack any tangible, physical manifestation that is not abstract.
With respect to dependent claim 18, the additional limitation that the hepatocyte is a cluster of hepatocytes refines the scope of the identification step, but the claims still lack any tangible, physical manifestation that is not abstract.
With respect to dependent claims 19 and 20, these claims do not add any additional limitations to either the identification step or the evaluation step; rather they specify that the method if only one of these. As such, neither of these claims results in any tangible, physical steps.
With respect to claim 21, this claim does not add meaningful limitations to obviate the abstract idea exception – the claim requires both identification and evaluation and indicates that what is identified is also evaluated.
With respect to claims 1-4 and 16-21, there are no active steps and the abstract idea is not integrated into a practical application
With respect to claims 22 and 23, these claims do add limitations that require physical steps (cultivating a hepatocyte and added a drug to the hepatocyte, enabling the method to function as a drug screening evaluation). However, these physical steps are not enough to integrate these claims into a practical application because the only active steps recited by the claims amount to simply implementing the abstract idea (e.g. collecting the data that will be used for identification and evaluation). These are considered merely data gather steps required to use the abstract idea; they do not provide enough additional elements to amount to significantly more than the abstract idea – they are only insignificant extra-solution activity.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1, 19, 20 and 24-27 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Park Yong Keun (KR 10-1855366, cited in IDS filed on Feb. 21, 2025).
Park Yong Keun teach methods for determining shapes of cells, including hepatocytes using the distribution data of refractive index of a sample containing cells. (paras. [0038]-[0040], [0043]-[0051], [0053], [0058], [0064]. As the method taught by Park Yong Keun must be able to distinguish cells from bile canaliculus (which are cell adjacent), the identification, or evaluation or both, apparatus and program are taught by the prior art such that the refractive index distribution data would enable bile canaliculus to be identified.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TERESA E KNIGHT whose telephone number is (571)272-2840. The examiner can normally be reached Monday-Friday 9-4.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached at 571-272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TERESA E KNIGHT/ Primary Examiner, Art Unit 1634